Skip to Main Content
Beta test
our new site.
(
NLM Technical Bulletin
)
Home
Search
Study Topics
Glossary
Full Text View
Tabular View
No Study Results Posted
Related Studies
Lume Lung 2 : BIBF 1120 Plus Pemetrexed Compared to Placebo Plus Pemetrexed in 2nd Line Nonsquamous NSCLC
This study is ongoing, but not recruiting participants.
Study NCT00806819 Information provided by Boehringer Ingelheim Pharmaceuticals
First Received on December 10, 2008. Last Updated on May 15, 2013
History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Carcinoma, Non-Small-Cell Lung
Additional conditions recognized in this trial
Carcinoma
More general conditions related to this trial
Bronchial Neoplasms
Carcinoma, Bronchogenic
Lung Diseases
Lung Neoplasms
Neoplasms
Neoplasms by Histologic Type
Neoplasms by Site
Neoplasms, Glandular and Epithelial
Respiratory Tract Diseases
Respiratory Tract Neoplasms
Thoracic Neoplasms
Interventions listed in this trial
Pemetrexed
Folic Acid
Placebo plus pemetrexed
BIBF1120
BIBF1120 plus pemetrexed
Additional drug interventions recognized in this trial
Hematinics
Vitamin B Complex
More general drug interventions related to this trial
Antimetabolites
Antimetabolites, Antineoplastic
Antineoplastic Agents
Enzyme Inhibitors
Folic Acid Antagonists
Growth Substances
Hematologic Agents
Micronutrients
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Physiological Effects of Drugs
Therapeutic Uses
Vitamins
Sponsors listed in this trial
Boehringer Ingelheim Pharmaceuticals
Back to top of Main Content
